Natco Pharma Limited
All news and filings related to Natco Pharma Limited.
View all news & filings- High impact
Natco Pharma approves ₹1,300 crore rights issue, revises demerger scheme
Natco Pharma approved a rights issue of up to ₹1,300 crore via equity shares of face value ₹2. A Fund-Raising Committee was formed. The company will also revise its demerger scheme with Natco Crop Health Sciences Limited to accommodate changes from the rights issue.
Read the summary - Low impact
Natco Pharma Announces 43rd AGM for FY26, Publishes Newspaper Notices
Natco Pharma Limited announced its 43rd Annual General Meeting for the fiscal year ending March 31, 2026. Newspaper notices were published on September 5, 2026, in Financial Express and Nava Telangana, as per SEBI regulations. These are also available on the company's website.
Read the summary - Medium impact
Natco Pharma schedules 43rd AGM for Sep 30, 2026; approves up to ₹2,000 Cr fundraising
Natco Pharma will hold its 43rd AGM on September 30, 2026, via VC/OAVM. The company plans to raise up to ₹2,000 crores through various fundraising methods including QIP. E-voting is open from September 27 to September 29, 2026.
Read the summary - Low impact
Natco Pharma Officials to Meet Investors on Sep 7
Natco Pharma officials will attend an investor meeting organized by Antique Stock Broking on September 7, 2026, in Hyderabad. The meeting is scheduled from 10:00 AM to 1:00 PM. No UPSI will be shared.
Read the summary - Medium impact
Natco Pharma Invests $14 Million in eGenesis for Organ Transplant Technology
Natco Pharma is investing US$ 14 million in eGenesis, Inc. through convertible promissory notes, bringing its total investment to US$ 22 million. The acquisition is expected to be completed by September 30, 2026. eGenesis pioneers genome engineering for organ transplantation.
Read the summary - Low impact
Natco Pharma to Participate in Investor Meetings on Aug 27-28, 2026
Natco Pharma officials will attend investor meetings on August 27-28, 2026. The meetings are organized by Nuvama Wealth Management and ICICI Securities in Mumbai and Hong Kong. No UPSI will be discussed.
Read the summary - Medium impact
Natco Pharma's Visakhapatnam Unit Completes US FDA Inspection with 4 Observations
Natco Pharma's Visakhapatnam FDF plant completed a US FDA inspection from August 17-21, 2026. The company received a Form 483 with 4 procedural observations, which it is confident of addressing.
Read the summary - Low impact
Natco Pharma to Participate in Investor Meetings from Aug 24-26, 2026
Natco Pharma Limited officials will attend an investor meeting organized by Nuvama Wealth Management and ICICI Securities in Singapore. The meeting is scheduled from August 24 to August 26, 2026. No UPSI will be discussed.
Read the summary - High impact
Natco Pharma FY26 Revenue at ₹43,759 Cr, PAT at ₹13,719 Cr
Natco Pharma's FY26 revenue reached ₹43,759 crore, with PAT at ₹13,719 crore and EPS of ₹79.20. Key segments include Export Formulations (₹32,345 Cr), Domestic Formulations (₹4,409 Cr), API (₹2,347 Cr), and CHS (₹1,382 Cr). The company is investing in advanced therapeutics and expanding its global presence, including a stake in Adcock Ingram.
Read the summary - Medium impact
Natco Pharma Q1 FY27 Earnings Call Transcript Released
Natco Pharma's Q1 FY27 consolidated revenues were ₹794.4 crores. EBITDA was ₹245.7 crores with a 30.9% margin. Profit after tax stood at ₹206.5 crores. Adcock Ingram's profit share was ₹84.3 crores, with Natco increasing its stake to 49%. Brazil revenue grew 180% to ₹178 crores. The company plans a ₹2,000 crore fundraise for acquisitions.
Read the summary - Low impact
Natco Pharma to Attend Investor Meetings by Nuvama Wealth & ICICI Securities
Natco Pharma Limited will participate in investor meetings organized by Nuvama Wealth Management and ICICI Securities from August 19-21, 2026, in Mumbai. No Unpublished Price Sensitive Information will be disclosed during these interactions.
Read the summary - Medium impact
Natco Pharma Publishes Unaudited Financial Results for Q1FY27 and Interim Dividend
Natco Pharma published its unaudited financial results for the quarter ended June 30, 2026. The company also declared an interim dividend for FY 2026-27. Newspaper publications were made on August 15, 2026.
Read the summary - Low impact
Natco Pharma Q1 FY27 Earnings Conference Call Audio Link Released
Natco Pharma released the audio weblink for its Q1 FY27 earnings conference call held on August 14, 2026. The recording is available on the company's website.
Read the summary - High impact
Natco Pharma Q1FY27: Revenue ₹7,944 Cr, PAT ₹2,065 Cr, EPS ₹11.53
Natco Pharma reported Q1FY27 revenue of ₹7,944 crore and PAT of ₹2,065 crore. EPS stood at ₹11.53. International Formulations contributed ₹4,771 crore, and Domestic Formulations ₹1,364 crore. The company received U.S. FDA approval for Eribulin Mesylate Injection. An earnings call is scheduled for August 14, 2026.
Read the summary - Medium impact
Natco Pharma declares interim dividend of ₹1.50 per share; record date Aug 20, 2026
Natco Pharma declared an interim dividend of ₹1.50 per equity share for FY 2026-27. The record date for this dividend is August 20, 2026, with payment starting August 26, 2026.
Read the summary - Medium impact
Natco Pharma Declares ₹1.50 Interim Dividend, Eyes ₹2000 Cr Fundraising
Natco Pharma declared an interim dividend of ₹1.50 per share for FY27. The company is exploring fundraising up to ₹2000 Crores. The 43rd AGM notice was approved. For Q1FY27, consolidated revenue was ₹794.4 Cr (down from ₹1,390.6 Cr) and profit was ₹206.5 Cr (down from ₹480.3 Cr).
Read the summary - Low impact
Natco Pharma to Host Q1FY27 Earnings Call on August 14, 2026
Natco Pharma will hold an earnings call on August 14, 2026, at 17:30 IST to discuss its Q1FY27 un-audited financial results for the quarter ended June 30, 2026. Key management will attend.
Read the summary - Medium impact
Natco Pharma Receives Tentative US FDA Approval for Olaparib Tablets
Natco Pharma received tentative U.S. FDA approval for Olaparib 100 mg and 150 mg tablets. Natco will manufacture the drug, with Alembic Pharmaceuticals handling U.S. distribution. Olaparib tablets had estimated U.S. sales of USD 1.4 billion for the 12 months ending March 2026.
Read the summary - Medium impact
Natco Pharma Acquires Additional 13.25% Stake in Adcock Ingram for ₹1,060 Crore
Natco Pharma completed the acquisition of an additional 13.25% stake in Adcock Ingram Holdings Proprietary Limited. This increases Natco's shareholding to 49% for approximately ₹1,060 crore (ZAR 1.81 billion). The acquisition is a strategic step in Natco's African growth.
Read the summary - Low impact
Natco Pharma Receives ₹60 Lakh Tax Demand Order
Natco Pharma received a tax demand order for ₹21.35 lakh, plus ₹17.18 lakh in interest and ₹21.35 lakh in penalty. The demand relates to the audit period April 2020 to December 2024 concerning RCM reporting. The company is evaluating its options.
Read the summary - Low impact
Natco Pharma files SEBI compliance certificate for Q1 FY27
Natco Pharma Limited submitted a SEBI compliance certificate for the quarter ended June 30, 2026. The certificate confirms processing of dematerialized securities and updating depositories as registered owners.
Read the summary - High impact
Natco Pharma to Invest ₹1400 Cr in Subsidiary, ₹1069 Cr in Adcock Ingram
Natco Pharma's Board approved investing up to ₹1,400 Crores in its South African subsidiary. Additionally, it will acquire a 49% stake in Adcock Ingram for ₹1,069 Crores, increasing its holding from 35.75%. Adcock Ingram reported US$ 423 million topline for 9MFY26. Acquisitions are expected to complete by July 2026.
Read the summary - Low impact
Natco Pharma Designates Two Senior R&D Executives
Natco Pharma designated Mr. Gnanadeva Chalapathy Gudipati as Senior Vice President - Analytical R&D and Mr. Madhava Rao Karicherla as Vice President - Formulation R&D. Both appointments are effective July 6, 2026. Their roles involve significant contributions to the company's research and development initiatives.
Read the summary - Medium impact
Natco Pharma Q4 FY26 Earnings Call Transcript Released
Natco Pharma's Q4 FY26 consolidated revenue was ₹816.9 Cr, down from ₹1,287.3 Cr. FY26 revenue was ₹4,375.9 Cr vs ₹4,784 Cr. FY27 revenue is projected at ₹3,400-3,500 Cr with PAT of ₹700-750 Cr. Key drivers include semaglutide and future exclusivities. The company plans international acquisitions.
Read the summary - Medium impact
Natco Pharma and Lupin Get US FDA Approval for Eribulin Mesylate Injection
Natco Pharma and Lupin announced U.S. FDA approval for Eribulin Mesylate Injection, 1 mg/2ml. This drug is bioequivalent to Halaven® Injection, which had estimated U.S. sales of USD 43.7 million in April 2026. The injection is used for metastatic breast cancer and liposarcoma.
Read the summary - Low impact
Natco Pharma: Newspaper Publication for Audited Financial Results (Q4FY26)
Natco Pharma Limited published its audited financial results for the quarter and year ended March 31, 2026. The information was disseminated through newspaper publications in Business Line and Nava Telangana on May 30, 2026, and is also available on the company's website.
Read the summary - Low impact
Natco Pharma Q4 FY26 Earnings Conference Call Transcript Released
Natco Pharma Limited released the transcript of its Q4 FY25-26 earnings conference call held on May 29, 2026. The transcript is available on the company's website. This is a routine disclosure following the earnings call.
Read the summary - High impact
Natco Pharma Q4FY26 Results: Revenue ₹8,169 Cr, PAT ₹2,690 Cr
Natco Pharma reported Q4FY26 revenue of ₹8,169 crore and PAT of ₹2,690 crore. FY26 revenue reached ₹43,759 crore with PAT of ₹14,185 crore. The company launched Semaglutide and Pomalidomide, and acquired a stake in Adcock Ingram. An earnings call is scheduled for May 29, 2026.
Read the summary - Medium impact
Natco Pharma Approves Audited FY26 Results, Amends CSR and Fair Disclosure Policies
Natco Pharma's Board approved audited standalone and consolidated financial results for the fiscal year and quarter ended March 31, 2026. The company also amended its CSR Policy and Code of Practices for Fair Disclosure of UPSI. The Board meeting concluded on May 29, 2026.
Read the summary - Low impact
Natco Pharma to Discuss Q4FY26 Audited Results on May 29, 2026
Natco Pharma will hold an earnings call on May 29, 2026, at 16:30 PM IST to discuss its audited financial results for Q4FY26 and the full fiscal year ended March 31, 2026. The call will feature senior management, including the CEO and CFO.
Read the summary - Low impact
Natco Pharma Receives Demand Notice of ₹4.92 Crore from NPPA
Natco Pharma received a demand notice from NPPA for ₹4.92 crore, including overcharge, penalty, and interest. The notice alleges overcharging for two drugs between April and November 2023. The company stated there is no material financial or operational impact.
Read the summary - Low impact
Natco Pharma Promoter Disclosures Filed for FY26 Under SEBI Takeover Regulations
Natco Pharma Limited filed disclosures under SEBI Takeover Regulations. Filings received from Promoter Sri V.C. Nannapaneni and other promoter group members. Disclosures cover the financial year ended March 31, 2026.
Read the summary - Low impact
Natco Pharma Files SEBI Compliance Certificate for Q4FY26
Natco Pharma Limited submitted a SEBI compliance certificate for the quarter ended March 31, 2026. The certificate confirms dematerialization of securities and updated ownership records within 15 days as per SEBI regulations.
Read the summary - Low impact
Natco Pharma: Trading Window Closed from April 1, 2026, for FY26 Financial Results
Natco Pharma's trading window will be closed from April 1, 2026, until 48 hours after the declaration of financial results for the quarter and year ending March 31, 2026. This is in compliance with SEBI (Prohibition of Insider Trading) Regulations.
Read the summary - Medium impact
Natco Pharma Reappoints Key Directors V.C. Nannapaneni, Rajeev Nannapaneni, and others.
Natco Pharma Limited confirmed the re-appointment of Sri V.C. Nannapaneni as Chairman & Managing Director, Sri Rajeev Nannapaneni as Vice Chairman & CEO, Sri P.S.R.K Prasad as Director, and Dr. Donthineni Linga Rao as Director. These appointments are effective from April 1, 2026. The resolutions were passed with significant majority via postal ballot.
Read the summary - High impact
Natco Pharma Approves Demerger of Agrochemicals Business, New Nigeria Subsidiary
Natco Pharma approved a demerger of its Agrochemicals business into Natco Crop Health Sciences Limited, with an appointed date of October 1, 2026. The company will also invest up to USD 100,000 (approx. ₹83 lakh) in a new Nigeria subsidiary and plans to liquidate its Australian subsidiary by September 2026.
Read the summary - High impact
Natco Pharma Launches Affordable Generic Semaglutide Injection in India
Natco Pharma launches generic Semaglutide Injection in India on March 21, 2026. Multi-dose vials are priced at ₹1,290/₹1,750 monthly, significantly cheaper than innovator brands. Pen devices launch in April 2026. This aims to increase patient accessibility to GLP-1 therapy.
Read the summary - Low impact
Natco Pharma to Participate in Investec Investor Conference on March 9, 2026
Natco Pharma Limited will attend the Investec Promoter and Founder Conference 2026 in Mumbai on March 9, 2026. The meeting is scheduled from 9 AM to 5 PM. No UPSI will be discussed. The schedule may change.
Read the summary - High impact
Natco Pharma Launches Pomalidomide Capsules Generic in US Market
Natco Pharma and Breckenridge Pharmaceutical have launched Pomalidomide Capsules, a generic version of Pomalyst®, in the U.S. market. The drug, used for multiple myeloma and Kaposi sarcoma, had estimated U.S. sales of USD 3.2 billion for the 12 months ending Sep'25. Natco believes it has 180 days of shared exclusivity.
Read the summary - Low impact
Natco Pharma Clarifies Eris Lifesciences Partnership for Semaglutide Launch
Natco Pharma is launching Semaglutide in India in March 2026 with marketing partners, including Eris Lifesciences. This partnership is in the ordinary course of business and has no material impact. The company received CDSCO approval on February 14, 2026.
Read the summary - Low impact
Natco Pharma Publishes Postal Ballot Notice in Newspapers
Natco Pharma Limited has published a Notice of Postal Ballot in the Financial Express and Nava Telangana newspapers on February 21, 2026, as per SEBI regulations. The notice is also available on the company's website.
Read the summary - Medium impact
Natco Pharma seeks member approval for director re-appointments and remuneration
Natco Pharma is seeking shareholder approval via postal ballot for the re-appointment of Sri V.C. Nannapaneni, Sri Rajeev Nannapaneni, Sri P.S.R.K Prasad, and Dr. D. Linga Rao. The re-appointments are for one-year terms starting April 1, 2026. E-voting will be open from February 23 to March 24, 2026.
Read the summary - Medium impact
Natco Pharma Q3 FY26 Earnings Call Transcript Released
Natco Pharma released its Q3 FY26 earnings call transcript. The company reported Q3 FY26 revenue of ₹705.4 crore and net profit of ₹151.3 crore. An interim dividend of ₹1.5 per share was declared. The company is pursuing acquisitions and expects FY26 revenue of ₹4,200-4,300 crore. Semaglutide launch is anticipated to drive domestic growth.
Read the summary - Medium impact
Natco Pharma Receives CDSCO Approval for Generic Semaglutide Injection in India
Natco Pharma received CDSCO approval for its generic Semaglutide Injection in India. The company plans to launch the product in the Indian market in March 2026. Semaglutide is used for type 2 diabetes treatment.
Read the summary - Medium impact
Natco Pharma Q3 FY26 Results: PAT ₹151.3 Cr, Revenue ₹647.3 Cr; Interim Dividend ₹1.50
Natco Pharma reported Q3 FY26 results with a net profit of ₹151.3 crore and revenue of ₹647.3 crore. For the nine months, profit was ₹1,149.50 crore on revenue of ₹3,339 crore. The company announced an interim dividend of ₹1.50 per share for FY26.
Read the summary - Medium impact
Natco Pharma's Chennai API Unit Receives Voluntary Action Indicated (VAI) Classification from US FDA
Natco Pharma's Chennai API unit received a Voluntary Action Indicated (VAI) classification from the US FDA following an inspection from November 17-21, 2025. The company received seven observations on Form-483. This classification is a key regulatory outcome for the facility.
Read the summary - Low impact
Natco Pharma: Earnings Call Audio Recording for Q3 FY26 Uploaded
Natco Pharma Limited has uploaded the audio recording of its earnings conference call for Q3 FY26, held on February 12, 2026. The recording covers the quarter and nine months ended December 31, 2025, and is available on the company's website.
Read the summary - Medium impact
Natco Pharma declares interim dividend of ₹1.50/share; sets Feb 18 as record date
Natco Pharma declared a third interim dividend of ₹1.50 per equity share for FY2025-26. The record date for determining eligible shareholders is set as February 18, 2026. Dividend payments will commence from February 26, 2026.
Read the summary - Low impact
Natco Pharma to Invest $300,000 in New Wholly Owned Subsidiary in Chile
Natco Pharma's Board approved incorporating a wholly owned subsidiary in Chile, NATCO Pharma Chile SPA. The company will invest up to US$ 300,000 (approx. ₹2.49 crore) in cash for 100% shareholding. The subsidiary will operate in the pharmaceuticals sector.
Read the summary - Medium impact
Natco Pharma Appoints Amit Parekh as CFO, S.V.V.N. Appa Rao Retires
Natco Pharma's CFO, Mr. S.V.V.N. Appa Rao, will retire on February 12, 2026. Mr. Amit Parekh is appointed as the new CFO from February 13, 2026. Mr. Kalakuntla Srinivas Rao also joins as EVP - Pharma Division from February 12, 2026.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio